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EASILY MISSED?
ANCA associated vasculitis
 OPEN ACCESS
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1Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK; 2Centre for Cardiovascular Science, Queen’s Medical Research
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What you need to know
• Consider ANCA associated vasculitis (AAV) in people with chronic
systemic symptoms and evidence of renal, pulmonary, ear, nose, and
throat, ophthalmic, or peripheral nerve disease
• Perform urinalysis in people presenting with persistent systemic
symptoms and in those with specific features of vasculitis (scleritis,
chronic dyspnoea, cough, haemoptysis, foot drop) because these
individuals have a high probability of multi-system disease
• Patients with haemoptysis plus other features of AAV warrant same
day hospital assessment to evaluate for pulmonary haemorrhage
Nicola, 44, goes to her general practitioner with a one month
history of fatigue and night sweats. Physical examination is
unremarkable. The duration of her symptoms prompts her GP
to consider systemic inflammatory disease. Urinalysis is positive
for blood and protein, and blood tests show new renal
impairment (serum creatine 327 μmol/L, estimated glomerular
filtration rate (eGFR) 13 mL/min/1.73m2) and evidence of an
inflammatory response (C-reactive protein 50 mg/L,
haemoglobin 103 g/L, platelets 461×109/L, albumin 33 g/L).
Nicola is referred urgently to her local renal unit and undergoes
kidney biopsy and testing for anti-neutrophil cytoplasmic
antibodies (ANCA). She is diagnosed with ANCA-associated
vasculitis.
What is ANCA associated vasculitis?
ANCA associated vasculitis (AAV) is an umbrella term for a
group of multi-system autoimmune small vessel vasculitides
that can present at any age and affect 20-25 people per million
per year in Europe.1 A typical GP practice with 8000 patients
can expect to see one new case approximately every five years.
AAV diseases include microscopic polyangiitis, granulomatosis
with polyangiitis (GPA, previously “Wegener’s
granulomatosis”), and eosinophilic granulomatosis with
polyangiitis (EGPA, previously “Churg-Strauss syndrome”).2
The conditions are characterised by formation of granulomas
and inflammation of small arteries, arterioles, venules, and
capillaries.3 Inflamed vessels may rupture (for example, causing
alveolar haemorrhage or a purpuric rash) or become occluded
(for example, causing segmental glomerular infarction), giving
rise to a broad array of clinical symptoms and signs related to
a systemic inflammatory response, end organ microvascular
injury, or the mass effect of granulomas.
What symptoms do patients develop?
AAV may present with constitutional symptoms suggestive of
chronic inflammatory disease (fatigue, weight loss, fever, night
sweats, myalgia, or polyarthralgia) or with specific features of
end-organ involvement. Almost any part of the body can be
affected, but the most commonly affected systems are the upper
airways, lungs, kidneys, eyes, and peripheral nerves. Therefore,
presenting symptoms include sinus pain, nasal discharge, or
crusting, ear pain, or deafness (from upper airways
involvement), cough, shortness of breath, wheeze or haemoptysis
(from lung involvement), and painful, red eyes (from scleritis).
Some patients may have weakness, numbness, or difficulty
walking, but many patients do not mention these symptoms,
and signs of peripheral neuropathy—such as foot drop or wrist
drop—should be specifically sought on examination. A classic
“vasculitic” purpuric skin rash is present in a minority of
patients. Common presenting symptoms are listed in box 1.
Correspondence to R Hunter robert.hunter@ed.ac.uk
This is one of a series of occasional articles highlighting conditions that may be more common than many doctors realise or may be missed at first presentation. The
series advisers are Anthony Harnden, professor of primary care, Department of Primary Care Health Sciences, University of Oxford, and Dr Kevin Barraclough, School
of Social and Community Medicine, University of Bristol. To suggest a topic for this series, please email us at practice@bmj.com.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2020;369:m1070 doi: 10.1136/bmj.m1070 (Published 14 April 2020) Page 1 of 5
Practice
PRACTICE
 o
n
 14 M
ay 2020 at University of Edinburgh. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.m1070 on 14 April 2020. Downloaded from 
Box 1: When to consider ANCA associated vasculitis
Consider a diagnosis of AAV in the following clinical circumstances.4 Any of
these features should prompt consideration of AAV; multiple features are
strongly suggestive of AAV.5 Figures in parentheses are the approximate
proportion of incident cases exhibiting each feature.5 6
• Vasculitic rash with systemic features (<20%)
• Purpuric (“vasculitic”) rash accompanied by features of systemic disease
(eg, fever, flu like symptoms, abnormal urinalysis, etc.). Note that an
isolated rash in the absence of these features is unlikely to be AAV and
a prominent rash at presentation is often more suggestive of immune
complex vasculitis such as IgA vasculitis (previously Henoch-Schönlein
purpura)
• Respiratory symptoms (~45%)
• Haemoptysis (or other features suggestive of alveolar haemorrhage—eg,
shortness of breath and acute drop in haemoglobin)
• Progressive shortness of breath/cough (particularly if accompanied by
systemic symptoms or fine crackles suggestive of pulmonary fibrosis)
• Refractory/steroid dependent asthma
•Ear, nose, and throat/upper airways symptoms (~45%)
• Long standing/persistent sinusitis or otitis
• Hearing loss/earache
• Nasal bridge collapse (a late sign of very advanced disease; see fig 1)
• Subglottic tracheal stenosis (which may be discovered through
investigation of dyspnoea, stridor, or incidentally at the time of elective
intubation for general anaesthetic)
• Eye symptoms (<20%)
• Painful, red eye (scleritis)
• Diplopia with proptosis (caused by retro‐orbital granulomatous mass)
• Nerve symptoms (~30%)
• Paraesthesia/weakness in keeping with mononeuritis multiplex or other
peripheral neuropathy; consider AAV in the absence of an alternative
explanation (eg, diabetes, B12 deficiency) and particularly in wrist drop
or foot drop
• Renal disease (~65%)
• Rising serum creatine (or falling eGFR) with more than a trace of blood
and protein on urinalysis (ie, suspected glomerulonephritis); in the early
phases of disease there may be no symptoms and eGFR may be near
normal
Who gets vasculitis?
Several genetic and environmental risk factors have been
identified, but most of the variation in incidence is accounted
for by patient age. Incidence rises progressively with age until
the mid-late 80s, so that the incidence in the population aged
over 70 is 80-90 per million per year1 and consequently AAV
is the leading cause of glomerulonephritis in this age group.7
However, AAV can present at any age—including in
childhood—and affects all ethnicities; the incidence is
approximately the same in women and men. Environmental risk
factors are absent in most cases but exposure to drugs such as
cocaine, hydralazine, and propylthiouracil has been implicated.3
Why is it missed?
Diagnosis of AAV is often delayed or missed because the
condition has virtually no pathognomonic features, and most
of the presenting symptoms are either general—and thus may
be misdiagnosed as another systemic disease8—or more specific
but attributed to more common diseases such as uncomplicated
sinusitis, asthma, or scleritis. For example, EGPA may present
with shortness of breath and wheeze and is often initially
misdiagnosed as refractory or frequently relapsing asthma.9
People with predominant myalgia may be misdiagnosed as
having polymyalgia rheumatica and—because corticosteroid
treatment partially treats AAV—correct diagnosis is delayed
until the steroid dose is weaned and other symptoms emerge.
Granulomatosis with polyangiitis with cavitating lung lesions
can be misdiagnosed as lung cancer.
Diagnosis can also be delayed or missed when symptoms in
disparate organs are not recognised as manifestations of a single
disease.10 A patient may attend separate clinics: ear, nose, and
throat (for nasal crusting), ophthalmology (for scleritis), and
neurology (for peripheral neuropathy) without anybody “joining
the dots” between these symptoms. Indeed, a UK case-control
study found that patients had frequent healthcare encounters in
the months before a new diagnosis of GPA, with nearly 20%
of patients attending two or more specialist clinic appointments
in the year before diagnosis (compared to ~5% of controls).10
Why does this matter?
There is a stark difference in patient outcomes when diagnosis
is delayed or missed: untreated, only one in 10 patients survives
beyond two years11—a prognosis that is worse than most cancers.
If promptly recognised, however, AAV responds well to
immunosuppressive treatment and has a prognosis akin to other
chronic inflammatory diseases. In randomised controlled trials,
60-90% of patients enter disease remission,8 12 and the 2 year
survival is 90-97%.13
This difference in survival stems from the degree of irreversible
organ damage that occurs before the diagnosis is made (fig 1).
This can also leave patients with long term symptoms—such
as painful paraesthesia, dyspnoea, deafness, or facial
deformity—or with life-limiting organ dysfunction such as
chronic kidney disease. The consequences of late diagnosis are
particularly apparent in the subset of people who have renal
involvement. In this group, delayed diagnosis and worse renal
function at presentation are associated with a higher risk of
end-stage renal disease and early mortality.14 15
How is it diagnosed?
Clinical
The diagnosis of AAV is clinical, supported by serological and
histological data. There are many possible presenting
symptoms—none more important than another for making the
diagnosis—and no isolated discriminating symptoms of AAV.
Rather, the key to diagnosis is prompt recognition of an
inflammatory disease pattern when multiple symptoms emerge,
especially if more than one organ system is implicated or in
combination with chronic systemic symptoms. Therefore, when
two or more of these symptoms develop concurrently, the index
of suspicion should be high5 (box 1).
Two clinical scenarios pose particular diagnostic difficulty. The
first is alveolar haemorrhage: it can be hard to recognise and is
devastating if missed. Alveolar haemorrhage may present with
haemoptysis, but this symptom is absent in up to half of cases.16
Some patients with extensive airspace bleeding will report only
of shortness of breath or cough and have a near normal chest
examination. Patients with haemoptysis plus other features of
AAV warrant same day hospital assessment to rule out
pulmonary haemorrhage without further primary care
investigations if these would delay referral (box 2). All other
patients with suspected vasculitis and dyspnoea or cough should
have a full blood count; if there is a recent drop in haemoglobin
(or a low haemoglobin with no historic comparator) then we
advise urgently discussing the possibility of pulmonary
haemorrhage with a specialty service.
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Box 2: First line investigations
First line investigations support a diagnosis of AAV by evaluating for a chronic
inflammatory response or renal failure or by testing for differential diagnoses
such as infection and cancer. Given the multi-system nature of AAV, and the
broad differential diagnosis, it is usually appropriate to request all of these
investigations in cases of suspected AAV. The only exception is the ANCA
test which would usually be requested by a specialist service.
• Urinalysis (consider AAV causing glomerulonephritis if more than a
trace of either blood or protein is detected; if abnormal then consider
quantifying proteinuria with a urine protein:creatine or albumin:creatine
ratio)
• Full blood count (normocytic anaemia/thrombocytosis/eosinophilia due
to chronic inflammation; microcytic anaemia in chronic covert blood loss
in low grade alveolar haemorrhage or gut involvement; rapidly falling
haemoglobin in acute alveolar haemorrhage)
• Urea and electrolytes (rising serum creatine/falling eGFR)
• Serum albumin (may be low due to inflammation or nephrotic range
proteinuria)
• C reactive protein or erythrocyte sedimentation rate (both measurements
are high in inflammation)
• Liver function tests, calcium (typically normal or near-normal in AAV,
so abnormalities might suggest an alternative diagnosis such as infection
or cancer)
• Chest radiography (may have nodular, fibrotic, or infiltrative lesions in
AAV; exclude lung cancer or infection)
• ANCA testing in liaison with specialty service
The second difficult scenario is AAV presenting as organ limited
disease, without systemic symptoms. For example, most patients
with isolated glomerulonephritis have no symptoms until renal
failure advances to the point of uraemia. Thus, consider AAV
in patients with falling eGFR with blood and protein on urine
dipstick even if they have no constitutional symptoms and full
blood count and C reactive protein results are normal.
The differential diagnosis of AAV includes cancer, chronic
infection (particularly bacterial endocarditis), and other
autoimmune conditions. Because of the difficulties in diagnosis,
discuss patients with possible or suspected AAV early with a
specialty service.
Investigations
Investigations can further support a diagnosis of AAV and refute
the major differential diagnoses of infection and cancer. As in
the case study, urinalysis can rapidly screen for renal
involvement in a multi-system disease. Patients with haematuria
or proteinuria in this context have a high probability of having
AAV. This probability is ~2% if the dipstick findings occur in
isolation, rising to 85% if there is concomitant sinus and
pulmonary disease.17 18
ANCA testing improves diagnostic certainty for patients with
a high pre-test probability of disease.18 However, up to 10% of
patients with small vessel vasculitis clinically test negative for
ANCA. Conversely, false positive results can occur in the
general population and in association with infections,
malignancy, and autoimmune gastrointestinal and renal disease.4
Given this complexity, ANCA tests are not usually requested
in primary care. Kidney or lung biopsies may be taken by
specialty services to confirm a diagnosis of AAV or exclude
differential diagnoses such as cancer.
How is it managed?
AAV is managed by a specialty service, which may be a
rheumatology, renal, respiratory, or dedicated vasculitis service.
It is treated with immunosuppressive therapies such as
glucocorticoids, cyclophosphamide, rituximab, azathioprine,
methotrexate, and mycophenolate mofetil. Adjunctive treatments
aim to reduce the risk of infections—particularly pneumocystis,
osteoporosis, diabetes, and cardiovascular disease.19
Case history outcome
Nicola was treated with glucocorticoids, cyclophosphamide,
plasma exchange, and rituximab. Her renal function initially
deteriorated before her disease entered remission, but she
avoided the need for dialysis. She now enjoys a good quality
of life and her renal function has improved and stabilised to a
serum creatine of 188 μmol/L/eGFR 25 mL/min/1.73m2. Without
prompt consideration of a multi-system illness in primary care,
Nicola would almost certainly have developed irreversible end
stage renal failure within weeks.
Education into practice
• Which investigations would you request in a patient who presented—like
Nicola—with a month of fatigue and night sweats?
• What would be the significance of blood and protein on urinalysis in such a
patient?
• How would you manage a patient with a new multi-system illness who
reported shortness of breath and haemoptysis?
How patients were involved in the creation of this article
Nicola Welsh is an author of this article. She was involved in planning the
content, writing her perspective and case history, and reviewing the final
manuscript.
Additional resources
• RCGP eLearning hosts 5 and 30 minute online learning modules aimed
at improving the recognition and diagnosis of ANCA vasculitis in primary
care https://www.thelaurencurrietwilightfoundation.org/gpcampaign/
A patient’s perspective
I initially visited my GP in August 2018 after feeling very tired and experiencing
headaches and nausea. I had been having some night sweats but had
self-diagnosed this as a peri-menopausal symptom. I was also caring for my
mum who had terminal cancer, and my two kids alongside running a charity
so put most of my symptoms down to stress and anxiety. I explained this to
my GP who said he would like to check some blood tests, which surprised
me. I thought he was just being thorough and fully expected the results to be
fine. The next day he called to explain that I needed to be admitted to hospital
as my kidneys were not working properly. My initial reaction was shock as I
still felt relatively well; however, in hindsight, there were a few minor “warning
signs” over the past year that I had ignored. These were very minor though,
and it is worrying that there were not more obvious signs that something was
wrong. I had no idea you could feel so well until things were so critical with
your kidneys. After a few tests including a kidney biopsy, I was diagnosed
with vasculitis. I was started on various treatments, including plasma exchange.
I am now on lots of medication and have 6 monthly rituximab infusions to
suppress my disease. I am back at work and although I have to take life a
little slower, I am generally very well and feeling good. I will be forever grateful
to my intuitive GP who really listened to me and didn’t delay in testing me.
This most likely saved me from dialysis and I can never thank him or the renal
team enough for their swift care. I really hope this is a reminder to other doctors
that testing early, with such minor symptoms, can be lifesaving.
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Figure
Fig 1 Clinical consequences of AAV. (a) Diffuse alveolar haemorrhage. (b) Nail fold infarction and splinter haemorrhages.
(c) Nasal bridge collapse resulting from chronic, erosive inflammation in the upper airways. Delayed diagnosis can
result in permanent disability/deformity and early mortality. Manifestations of advanced disease such as a “saddle
nose” deformity are relatively rare but can still occur if a diagnosis of AAV is missed (these images are not directly
related to the case study in this article)
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